Mirum Pharmaceuticals, Inc. · NASDAQ:MIRM

Mirum Pharmaceuticals — Q3 2026 Earnings Presentation

79 slides from Mirum Pharmaceuticals's earnings presentation, Nov 3, 2026

  1. Slide 1: Delivering High Impact Medicines for Rare Disease

    MIRUM PHARMACEUTICALS DELIVERING HIGH IMPACT MEDICINES FOR RARE DISEASE October 2026

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in

  3. Slide 3: Delivering Significant Value Through a Purpose-Built Rare Disease Model

    ® $680-700M2 10 Approved or Clinical Stage Indications in Development 5 approved indications; 4 in late-stage development 5 FDA Breakthrough Therapy Designations3 $4B+ Peak Revenue Potential of Mirum Portfolio4 High impact medicines for patients with rare liver and genetic diseases 2022 2023 2024 20

  4. Slide 4: Driving Growth Through Focus on Rare Liver, Rare Genetic Diseases

    Driving Growth Through Focus on Rare Liver, Rare Genetic Diseases Portfolio with Multi-Billion Dollar Revenue Potential1 Rare Liver Disease Business Global Commercial Reach ALGS, PFIC LIVMARLI Ultra-Rare Cholestasis $1Bn+ Volixibat PSC & PBC $1Bn+ Brelovitug HDV $1Bn+ Rare Genetic Disease Business C

  5. Slide 5: Commercial Portfolio with Pipeline of Growth Opportunities

    Commercial Portfolio with Pipeline of Growth Opportunities 4 APPROVED RARE DISEASE MEDICINES, 5 ADDITIONAL INDICATIONS IN DEVELOPMENT IN HIGH-NEED ORPHAN INDICATIONS Indication Preclinical Phase 1 Phase 2 and Phase 3 Approved Alagille Syndrome (ALGS)1 FDA and EMA approved Progressive Familial FDA an

  6. Slide 6: Rare Liver Diseases

    RARE LIVER DISEASES Significant Expansion Opportunities within Pipeline Indications 6

  7. Slide 7: LIVMARLI

    LIVMARLI® Alagille Syndrome (ALGS) Progressive Familial Intrahepatic Cholestasis (PFIC) 7

  8. Slide 8: IBAT Inhibition in Pediatric Cholestatic Liver Disease

    IBAT Inhibition in Pediatric Cholestatic Liver Disease Targeting IBAT Removes Circulating Bile Acids Addressing Toxic Bile Acid Accumulation Cholestatic Liver Disease Targeting IBAT Lowers Bile Acids IBAT Inhibition Clinical Benefits1-5 Defined by impaired bile flow & Mechanism directly addresses he

  9. Slide 9: LIVMARLI: A Leading Medicine for Rare Cholestatic Pruritus

    LIVMARLI: A Leading Medicine for Rare Cholestatic Pruritus 69% $360M YoY Growth $213M $142M $75M Available in Both Oral Solution and Tablet Formulation 2022 2023 2024 2025 Annual Net Product Sales MIRUM PHARMACEUTICALS 9

  10. Slide 10: Expanding Impact in Rare Cholestatic Pruritus

    Expanding Impact in Rare Cholestatic Pruritus Path to Sustained Long-Term EXPAND Growth PFIC Phase 3 Biliary Atresia ✓ Continued growth in new Rx 2,000 US/EU addressable ✓ Strong adherence & persistence sNDA submission targeted H1 ‘27 ✓ Weight-based dosing ALGS Approved ✓ Int’l market expansion 4,00

  11. Slide 11: LIVMARLI Label Expansion Opportunity in Cholestatic Pruritus

    LIVMARLI (MARALIXIBAT) Label Expansion Opportunity in Cholestatic Pruritus

  12. Slide 12: LIVMARLI Label Expansion Opportunity in Cholestatic Pruritus

    LIVMARLI Label Expansion Opportunity in Cholestatic Pruritus Broad Unmet Need in Multiple Ultra-Rare Cholestatic Conditions Pruritus in Ultra-Rare Characteristic Estimated Addressable Cholestatic Settings Cholestatic Burden US/EU Biliary Atresia Patients1 Elevated sBA 2,000 e.g., Biliary Atresia, Se

  13. Slide 13: EXPAND Phase 3 Study

    EXPAND Phase 3 Study Key Inclusion Criteria 20wk +20wks • Diagnosis of cholestatic liver disease excluding ALGS, PFIC, Maralixibat 285 ug/kg BID1 PSC, PBC, and ICP Maralixibat n=52 Open Label Extension • Moderate to severe cholestatic Placebo pruritus • Total serum bile acids >2×ULN Primary Endpoint

  14. Slide 14: EXPAND Phase 3 Baseline Demographics

    EXPAND Phase 3 Baseline Demographics – All Pediatric Population MRX Placebo (N=22) (N=24) Age at enrollment in years (SD) 6.6 (4.4) 6.0 (4.0) Sex (Female %) 10 (45.5) 11 (45.8) ItchRO(Obs) Score (SD) 2.65 (0.96) 2.65 (0.70) sBA, mol/L (SD) 149.7 (92.9) 155.4 (98.6) ALT, U/L (SD) 95.4 (59.4) 134.2 (

  15. Slide 15: EXPAND Phase 3 Primary Endpoint Met

    EXPAND Phase 3 Primary Endpoint Met Rapid, Sustained, Clinically Meaningful Reductions in Pruritus; sNDA Submission Planned 1H 2027 Average Pruritus Score (ItchRO[Obs]) Over 20 Weeks (All Pediatric Population) Biliary Atresia Subgroup 0 -1.15 CFB in ItchRO(Obs)2 PBO-adjusted reduction; p=0.0002 -0.5

  16. Slide 16: EXPAND Phase 3 Safety Summary

    EXPAND Phase 3 Safety Summary (Safety Population) MRX Placebo n (%) (n=25) (n=27) Participants with any treatment-emergent adverse event (TEAE) 24 (96.0) 26 (96.3) Grade 3 or higher TEAEs 6 (24.0) 6 (22.2) Related to study drug 1 (4.0) 0 Serious TEAEs 5 (20.0) 5 (18.5) TEAE that led to death 0 0 TEA

  17. Slide 17: Volixibat

    VOLIXIBAT IBAT Inhibitor for Cholestasis in Adults (PSC, PBC) 17

  18. Slide 18: Primary Sclerosing Cholangitis

    PRIMARY SCLEROSING CHOLANGITIS 18

  19. Slide 19: PSC: A Rare Immuno-Inflammatory Cholestatic Liver Disease

    PSC: A Rare Immuno-Inflammatory Cholestatic Liver Disease Progressive Biliary Injury Drives Serious and Compounding No Approved Therapies Cholestasis and Liver Damage1 Disease Consequences1-4 Significant Need Pruritus and Fatigue Heavy symptom burden Elevated Laboratory Tests Progressive biliary str

  20. Slide 20: PSC: Pruritus is Common and Often Moderate to Severe

    PSC: Pruritus is Common and Often Moderate to Severe Pruritus is a Registrational Endpoint Pruritus Is a Significant Burden No Approved Therapies; Significant Opportunity in PSC 8 PSC US Patients with Pruritus Often Moderate to Severe Median worst itch score (0-10 NRS) from last itching episode1 ~30

  21. Slide 21: Phase 2b Study of Volixibat in PSC Patients with Cholestatic Pruritus

    Phase 2b Study of Volixibat in PSC Patients with Cholestatic Pruritus GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION PSC patients with pruritus 28wk 2+ years VLX 20mg BID1 VLX Open Label Extension PBO Primary Endpoint Change in pruritus from baseline to 28wk2 Primary Cohort, n=111 (moderate to severe

  22. Slide 22: VISTAS Phase 2b Baseline Demographics – Primary Cohort

    VISTAS Phase 2b Baseline Demographics – Primary Cohort VLX 20 mg Placebo (N=54) (N=57) Age at enrollment in years (SD) 45.2 (15.7) 44.3 (14.2) Sex (Female %) 25 (46.3) 35 (61.4) Adult ItchRO Score (SD) 6.3 (1.6) 6.1 (1.5) PSC Type (Large Duct %) 49 (90.7) 53 (93.0) sBA in mol/L (SD) 109.6 (137.5) 6

  23. Slide 23: VISTAS Phase 2b Met Primary Endpoint

    VISTAS Phase 2b Met Primary Endpoint Rapid, Sustained, Clinically Meaningful Reductions in Pruritus Average Pruritus Score (Adult ItchRO) Over 28 Weeks 0 56% CFB in Adult ItchRO** ≥2 point reduction in pruritus -1 PBO -1.08 Improvement -2 -1.64 (0.241)* Serum Bile Acids Statistically significant red

  24. Slide 24: VISTAS: Improvements in Fatigue & Sleep

    VISTAS: Volixibat Treatment Showed Improvements in Fatigue & Sleep Change in PROMIS Fatigue and Sleep Scores at Week 281 1 Fatigue Sleep Disturbance LS Mean CFB in PROMIS domain scores 0 -0.78 -1 -1.89 -2 Improvement -3 -4 -4.22 -5 -2.33 (P=0.1322) -6 -6.47 -7 -8 -5.69 (P=0.0011)2 VLX 20 mg BID Plac

  25. Slide 25: VISTAS Phase 2b Safety Summary

    VISTAS Phase 2b Safety Summary (Primary and Secondary Cohorts) VLX 20 mg Placebo n (%) (N=77) (N=81) Participants with any treatment emergent adverse event (TEAE) 72 (93.5) 68 (84.0) Grade 3 or higher TEAEs 10 (13.0) 9 (11.1) Serious TEAEs 8 (10.4) 5 (6.2) TEAE that led to death 0 1 (1.2) TEAE that

  26. Slide 26: TEAEs Occurring in ≥5% of Patients

    TEAEs Occurring in ≥5% of Patients (Primary and Secondary Cohorts) VLX 20 mg Placebo n (%) (N=77) (N=81) Diarrhea 31 (40.3) 7 (8.6) Abdominal Pain 14 (18.2) 8 (9.9) Nausea 10 (13.0) 3 (3.7) Vitamin D deficiency 8 (10.4) 4 (4.9) Abdominal pain upper 7 (9.1) 6 (7.4) ALT increased 7 (9.1) 3 (3.7) Upper

  27. Slide 27: Primary Biliary Cholangitis

    PRIMARY BILIARY CHOLANGITIS

  28. Slide 28: PBC: A Chronic, Progressive, Immune-Mediated Cholestatic Disease

    PBC: A Chronic, Progressive, Immune-Mediated Cholestatic Disease Destruction of Intrahepatic Slow Progressing, with Serious Most Prevalent Bile Ducts Causes Cholestasis and Compounding Disease Cholestatic Liver and Liver Damage1 Consequences1,2 Disease ~85,000 Pruritus and Fatigue Heavy symptom burd

  29. Slide 29: PBC: Pruritus is Common and Often Moderate to Severe

    PBC: Pruritus is Common and Often Moderate to Severe Significant Opportunity Across 1st & 2nd Line Settings Pruritus Significantly impacts daily QoL 60% controlled 31k ~50k on UDCA with active (1st Line) I found myself itching my arms so ~85k pruritus much that I had bruises on my arms... - Rose, pa

  30. Slide 30: Phase 2b Study of Volixibat in PBC Patients with Cholestatic Pruritus

    Phase 2b Study of Volixibat in PBC Patients with Cholestatic Pruritus Positive Interim Analysis Rapid and statistically significant improvement in pruritus PBC patients with moderate-to-severe pruritus 28wk 2+ years Reductions in sBA and VLX 20mg BID1 VLX Open Label improvements in fatigue Extension

  31. Slide 31: VANTAGE Interim Analysis: Reduction in Pruritus from Baseline

    VANTAGE Interim Analysis: Reduction in Pruritus from Baseline Rapid and Statistically Significant Reductions in Pruritus 1 Average Pruritus Score (Adult ItchRO) Over 28 Weeks 0 PBO Adjusted CFB in Adult ItchRO1 -1 Response2: -2 Improvement -3 VLX 20mg -2.4 (P=0.0039) -4 VLX 80mg -2.6 -5 (P=0.0010) -

  32. Slide 32: Brelovitug

    BRELOVITUG Chronic Hepatitis Delta Virus (HDV) 32

  33. Slide 33: HDV Is the Most Severe Form of Viral Hepatitis

    HDV Is the Most Severe Form of Viral Hepatitis A Rapidly Progressive Disease with Significant Unmet Need Hepatitis Delta Virus >50% Liver-Related Death in 10 Years1 ~15,000 US pts diagnosed, insured, under care4 5yrs Avg. Progression to Cirrhosis and Liver Failure2 ~40,000 Est. US Prevalence Require

  34. Slide 34: Brelovitug AZURE-1 Phase 2b/3 Study Design

    Brelovitug: Preliminary Efficacy and Favorable Safety Profile in HDV Brelovitug AZURE-1 Phase 2b/3 Study Design 24wk Fully human anti-HBsAg monoclonal antibody SC injection 1x Weekly or 1x Monthly 300mg 1x Weekly or 900mg 1x Monthly1 Extension (96wks) Delayed Tx→ 300mg 1x Delayed Tx Start Weekly Pri

  35. Slide 35: AZURE-1 Phase 3 Key Baseline Disease Characteristics

    AZURE-1 Phase 3 Key Baseline Disease Characteristics 300 mg QW 900 mg Q4W Delayed Treatment N=59 N=65 N=29 Cirrhosis, n (%)1 24 (41) 27 (42) 12 (41) Liver stiffness, kPa, mean (SD) 14.3 (10.78) 13.7 (8.01) 14.6 (11.49) ALT, U/L, mean (SD) 130.4 (106.88) 121.3 (95.07) 121.0 (84.29) ALT ≥5x ULN, n (%)

  36. Slide 36: AZURE-1 Phase 3 Week 24 Met Primary Endpoint

    AZURE-1 Phase 3 Week 24 Met Primary Endpoint 300 mg QW* 900 mg Q4W Delayed Treatment N=59 N=65 N=29 Primary Endpoint 33/59 (56%) 29/65 (45%) 0/29 (0%) (Virologic Response + ALT normalization) p <0.0001 p <0.0001 Virologic response 51/59 (86%) 55/65 (85%) 0/29 (0%) HDV RNA ≥2 log10 reduction or TND H

  37. Slide 37: AZURE-1 Phase 3 Safety Through Week 24

    AZURE-1 Phase 3 Safety Through Week 24 300 mg QW 900 mg Q4W Delayed Treatment Participants who experienced, n (%) N=59 N=65 N=29 AEs Any 27 (45.8) 40 (61.5) 8 (27.6) Related to treatment 14 (23.7) 22 (33.8) 0 Grade 3+ 0 0 1 (3.4)* Serious 0 0 1 (3.4)* AE leading to discontinuation of study drug, n (

  38. Slide 38: AZURE-1 Phase 2b: Responses Continue to Deepen at Week 48

    AZURE-1 Phase 2b: Responses Continue to Deepen at Week 48 No New Safety Signals Observed Through 48 Weeks of Treatment 300 mg QW 900 mg Q4W N=20a N=20 24 wks 48wks 24 wks 48 wks Primary Endpoint 45% 35% 55% 55% (Virologic Response + ALT normalization) p = 0.003 p = 0.024 Virologic response 100% 95%b

  39. Slide 39: Ongoing Brelovitug Phase 3 Trials Supporting FDA and EMA Submissions

    Ongoing Brelovitug Phase 3 Trials Supporting FDA and EMA Submissions No ALT Limitation for Study Participation 24wk FDA Registration AZURE-1 n~200 300mg 1x Weekly Extension (96wks) 2:2:1 vs 900mg 1x Monthly vs Delayed Tx Start Delayed Tx→ 300mg 1x Weekly Enabling Studies Primary Endpoint Topline Dat

  40. Slide 40: Rare Genetic Diseases

    RARE GENETIC DISEASES Expanding Presence in Rare Genetic Diseases 40

  41. Slide 41: Bile Acid Portfolio: CHOLBAM & CTEXLI

    BILE ACID PORTFOLIO CHOLBAM® & CTEXLI® 41

  42. Slide 42: Bile Acid Replacement Therapies for Rare Genetic Diseases

    Bile Acid Replacement Therapies for Rare Genetic Diseases Bile Acid Replacement Therapies Provide Bile Acids the Liver Cannot Produce Impaired Bile Acid Synthesis Bile Acid Replacement Therapies Driven by single-enzyme defects and peroxisomal (PEX) disorders 7-DHC Smith-Lemli-Optiz Syndrome (SLOS) ✓

  43. Slide 43: Growing Business with Significant Commercial Synergies

    Growing Business with Significant Commercial Synergies Bile Acid Portfolio Addresses Increased Awareness & Multiple High Need Settings Diagnosis Driving Growth $161 CTX Approved $123 $109 $103 BASD PBD-ZSD Approved 2022 2023 1 2024 2025 Annual Net Product Sales ($M) 1 Travere Therapeutics, Inc. and

  44. Slide 44: ATEBRIOZ (Zilurgisertib)

    ATEBRIOZ (ZILURGISERTIB) Fibrodysplasia Ossificans Progressiva (FOP) 44

  45. Slide 45: ALK2 Inhibition in Fibrodysplasia Ossificans Progressiva (FOP)

    ALK2 Inhibition in Fibrodysplasia Ossificans Progressiva (FOP) Targeting ALK2 Receptor Reduces Volume of Heterotopic Ossification in FOP Patients Fibrodysplasia Ossificans Ultra-Rare ALK2 Inhibition Benefits Progressiva Genetic Disorder Observed2 ACVR1 gene mutation results in aberrant overactivatio

  46. Slide 46: ATEBRIOZ (zilurgisertib) Now FDA Approved

    ATEBRIOZ (zilurgisertib) Now FDA Approved FDA-approved to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP) Please see full Prescribing Information MIRUM PHARMACEUTICALS 46

  47. Slide 47: Pivotal Phase 2 Results from Cohort 1 of PROGRESS Study

    Pivotal Phase 2 Results from Cohort 1 of PROGRESS Study Meaningful Reductions in Total HO Lesion Volume, New HO Lesions and Flare Activity Primary Endpoint Secondary Endpoint: Secondary Endpoint: 81% reduction in proportion of patients with new lesions Wk 24 Reduction in total lesion Fewer mean annu

  48. Slide 48: PROGRESS Cohort 1 Safety

    PROGRESS Cohort 1 Safety Zilurgisertib 100 mg Placebo Participants who experienced, n (%) (n=32) (n=31) TEAE 29 (90.6) 30 (96.8) Patients with treatment-related TEAE 15 (46.9) 11 (35.5) Patients with serious TEAE 2 (6.3) 3 (9.7) Patients with grade ≥3 TEAE 2 (6.3) 4 (12.9) Patients with fatal AE 0 0

  49. Slide 49: PROGRESS Phase 2 Pivotal Study Design

    ATEBRIOZ (zilurgisertib) Expansion into Younger FOP Patients PROGRESS Phase 2 Pivotal Study Design Study conducted by Incyte Mirum responsible for commercialization Cohort 1 FOP Patients ≥12 y.o.1; n=63 COMPLETED 24wk Zilurgisertib 100 mg QD Cohort 2 Open Label FOP Patients 6 <12 y.o.2; n=25 Extensi

  50. Slide 50: MRM-3379

    MRM-3379 PDE4D Inhibitor for Fragile X Syndrome (FXS) 50

  51. Slide 51: Fragile X Syndrome (FXS): Rare X-Linked Genetic Disorder

    Fragile X Syndrome (FXS): Rare X-Linked Genetic Disorder Mutation in the X-linked FMR1 gene Decreases cAMP • Leading inherited form of intellectual disability and autism spectrum disorder FMRP cAMP cAMP cAMP cAMP • Symptoms more pronounced in males • Diagnosed by genetic testing ~50,000 Males in the

  52. Slide 52: MRM-3379: Selective PDE4D inhibitor for FXS

    MRM-3379: Selective PDE4D inhibitor for FXS PDE4D MRM-3379 Regulates cellular signaling by breaking down cAMP Highly expressed in brain • Oral, selective PDE4D inhibitor regions critical for learning, memory, emotional regulation • 5:1 brain/plasma ratio, potentially increasing therapeutic window In

  53. Slide 53: Phase 2 Study of MRM-3379 in Fragile X Syndrome

    Phase 2 Study of MRM-3379 in Fragile X Syndrome 12wk Primary Endpoint 16-45 years, N=52 MRM-3379: 3 Dose Arms Safety & tolerability 1:1:1:1 Primary and PBO Secondary 13 to <16 years, Endpoints N=8 MRM-3379 Open Label Key Secondary Endpoint Key Inclusion Criteria NIH-TCB Crystallized • Males, 13-45 y

  54. Slide 54: Mirum Pharmaceuticals

    MIRUM PHARMACEUTICALS Delivering High Impact Medicines for Rare Disease 54

  55. Slide 55: Well-Positioned to Execute on Our Planned Strategy

    Well-Positioned to Execute on Our Planned Strategy 5 potential approval and label expansion opportunities expected 2026 2027 2026 FY Guidance ✓ VISTAS (PSC) positive topline results ❑ VANTAGE (PBC) topline results in Q1 ✓ AZURE-1 (HDV) positive interim analysis ❑ Brelovitug HDV BLA submission in H1

  56. Slide 56: Thank You

    THANK YOU mirumpharma.com ©2026 Mirum Pharmaceuticals, Inc. All rights reserved. All service marks, trademarks and tradenames appearing in this presentation are the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to in this presentation appear with

  57. Slide 57: Supplemental Materials

    SUPPLEMENTAL MATERIALS 57

  58. Slide 58: LIVMARLI Important Safety Information

    LIVMARLI Important Safety Information IMPORTANT SAFETY INFORMATION LIVMARLI can cause serious side effects, including: Liver injury: Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In

  59. Slide 59: ATEBRIOZ Important Safety Information

    ATEBRIOZ Important Safety Information IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS - Embryo-Fetal Toxicity • Can cause fetal harm. Verify females of reproductive potential are not pregnant prior to initiating ATEBRIOZ and advise of the potential risk to a fetus and to use effective contrace

  60. Slide 60: CHOLBAM Important Safety Information

    CHOLBAM Important Safety Information LIMITATIONS OF USE The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders, including Zellweger spectrum disorders, have not been established. IMPORTANT SAFETY I

  61. Slide 61: CTEXLI Important Safety Information

    CTEXLI Important Safety Information IMPORTANT SAFETY INFORMATION CTEXLI can cause side effects, including: Liver Injury: You will need to undergo laboratory testing before starting and while taking CTEXLI to check your liver function. Changes in certain liver tests may occur during treatment and may

  62. Slide 62: Mirum Quarterly Net Product Sales

    Mirum Quarterly Net Product Sales Net Product Sales ($M) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Q1 2026 Q2 2026 LIVMARLI US 49.5 56.9 64.2 74.0 244.7 83.9 92.1 LIVMARLI International 23.7* 31.2* 28.1* 32.3 115.3 29.8 36.5* LIVMARLI Total 73.2 88.2 92.2 106.4 360.0 113.7 128.7 BAP Total 38.4 39.6 40

  63. Slide 63: Mirum Quarterly Income (Loss) from Operations

    Mirum Quarterly Income (Loss) from Operations $M Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Q1 2026 Q2 2026 Total revenue 111.6 127.8 133.0 148.9 521.3 159.9 176.2 Less: Cost of sales (excluding intangible amortization and other non-cash expenses) 17.1 17.5 19.6 22.5 76.7 22.1 23.7 General and administ

  64. Slide 64: LIVMARLI Available in Both Oral Solution and Tablet Formulation

    Supplemental Material LIVMARLI Available in Both Oral Solution and Tablet Formulation Flexible Dosing Options for Patients 10mg 15mg 20mg 30mg Size for comparison One LIVMARLI Tablet Per Dose MIRUM PHARMACEUTICALS 64

  65. Slide 65: ALGS: A Debilitating Disease with Severe Cholestasis

    Supplemental Material ALGS: A Debilitating Disease with Severe Cholestasis Alagille Syndrome Genetic disease leading to severe cholestasis, unbearable pruritus and multi-system effects Lowers Serum Bile Acids 83% of patients experienced ≥20% reduction in sBA levels 88% Affected by Significantly 84%

  66. Slide 66: ICONIC: ALGS Pivotal Study Shows Significant Long-term Benefit

    Supplemental Material ICONIC: ALGS Pivotal Study Shows Significant Long-term Benefit Clinically Meaningful and Sustained Improvements in Pruritus, sBA, Growth, and QoL from Baseline.1 Reduced Pruritus 0 -0.5 84% ItchRO(Obs) -1 of participants experienced -1.5 clinically meaningful -2 improvements (≥

  67. Slide 67: Significant Improvement in Transplant-Free Survival in Patients with ALGS

    Supplemental Material Significant Improvement in Transplant-Free Survival in Patients with ALGS Treated with LIVMARLI Post-hoc Analysis of Long-Term Impact: >1-point Reduction in ItchRO[Obs] Was a Predictor of Transplant-Free Survival* Transplant-Free Survival Over 6 Years of Treatment with LIVMARLI

  68. Slide 68: PFIC: Progressive Diseases of Bile-Related Transporters

    Supplemental Material PFIC: Progressive Diseases of Bile-Related Transporters PFIC (Progressive Familial Intrahepatic Cholestasis) Multiple genetic subtypes Significant Improvements in Pruritus, Serum Bile Acids, and Bilirubin Severe pruritus Stunted growth Improvements Consistent Across Multiple Su

  69. Slide 69: MARCH PFIC: Positive Phase 3 Data Across Broad Spectrum of PFIC Types

    Supplemental Material MARCH PFIC: Positive Phase 3 Data Across Broad Spectrum of PFIC Types Significant Pruritus Improvements in All-PFIC Patients LIVMARLI Placebo (n=33) (n=31) 0.0 Proportion of Change from baseline in pruritus pruritus score morning score (ItchRO[Obs]) -0.5 -0.6 assessments ≤ 1 po

  70. Slide 70: MARCH PFIC: Significant Improvements in Markers of Liver Disease

    Supplemental Material MARCH PFIC: Significant Improvements in Markers of Liver Disease Significant Improvements in All-PFIC Patients (PFIC1, PFIC2, PFIC3, PFIC4, PFIC6) Serum Bile Acid Bilirubin1 50 4 LIVMARLI (n=33) Placebo (n=31) Change from baseline in serum BA, µmol/L LIVMARLI Placebo 3 3 Change

  71. Slide 71: PFIC: Treatment with LIVMARLI Demonstrates Improved EFS

    Supplemental Material PFIC: Treatment with LIVMARLI® (maralixibat) Demonstrates Improved EFS Event-Free Survival (EFS) of LIVMARLI-Treated PFIC Patients Compared with Real-World Data of Untreated Patients from NAPPED1 100 80 Maralixibat (N=41) Event−free survival, % 60 40 NAPPED (N=256) 20 EFS: surg

  72. Slide 72: Well-Characterized Safety Profile of LIVMARLI

    Supplemental Material Well-Characterized Safety Profile of LIVMARLI Safety Data Most common adverse GI adverse reactions 6% of patients of LIVMARLI includes 5 Years events were diarrhea were generally mild or experienced dose reductions of follow-up from 3 and abdominal pain moderate severity or int

  73. Slide 73: AZURE-1 Phase 2b: Rapid and Sustained Reductions in HDV RNA and ALT

    Supplemental Material AZURE-1 Phase 2b: Rapid and Sustained Reductions in HDV RNA and ALT HDV RNA ALT 6 150 HDV RNA, log10 IU/mL, mean (SE) 5 125 ALT, U/L, mean (SE) 4 100 3 75 2 50 Male ULN 1 Female ULN LLOQ 25 0 0 0 4 12 20 24 0 4 12 20 24 Week Week Treatment Group: 300 mg QW 900 mg Q4W Delayed tr

  74. Slide 74: Intellectual Property Overview

    INTELLECTUAL PROPERTY OVERVIEW 74

  75. Slide 75: LIVMARLI IP Coverage in the United States to 2040+

    LIVMARLI IP Coverage in the United States to 2040+ Indication Method of Treatment: Dosing (2031, 2040) Orange Book Listed – Patent No. 11,229,647 / 11,497,745 / 11,918,578 / 11,260,053 Method of Treatment (2032, 2037) Orange Book Listed – Patent No. 11,376,251 ALGS Orphan Designation (2030) [Pending

  76. Slide 76: IP Coverage for Pipeline Indications in the United States: Volixibat

    IP Coverage for Pipeline Indications in the United States Indication Method of Treatment: Dosing (2043) Patent No. 12,576,079 PBC Granted Orphan Designation, 7 years from approval PSC Granted Orphan Designation, 7 years from approval PBC Method of Treatment: PBC (2032) Volixibat PSC Patent No. 12,57

  77. Slide 77: IP Coverage for Pipeline Indications: Brelovitug, MRM-3379, FOP

    IP Coverage for Pipeline Indications in the United States Indication ® CTX Orphan Designation (2032) Composition of Matter (2041) Brelovitug HDV Patent No. 11,932,681 MRM-3379 FXS Composition of Matter (2039)1 Patent No. 9,120,770 Orphan Drug Designation (2033) FOP Composition of Matter (2040)1 Pate

  78. Slide 78: LIVMARLI IP Coverage in Europe to 2040+

    LIVMARLI IP Coverage in Europe to 2040+ Indication [Approved for Grant] Method of Treatment: Dosing (2040) Orphan Designation (2034) ALGS Method of Treatment (2032, Spain and France 2037) Patent No. 2,771,003 [Pending] Formulation, Manufacturing, Additional Dosing (2042) [Approved for Grant] Method

  79. Slide 79: IP Coverage for Pipeline Indications in Europe

    IP Coverage for Pipeline Indications in Europe Indication Composition of Matter (2027) Patent No. 2,084,172 PBC Granted Orphan Designation, 10 years from approval PBC Volixibat PSC PSC Granted Orphan Designation, 10 years from approval [Pending] Method of Treatment: Dosing (2040) [Pending] Formulati

Mirum Pharmaceuticals — Q3 2026 Earnings Presentation on 6ix